What is Liquidia?
Liquidia Corporation, operating through its subsidiary Liquidia Technologies, Inc., is a late-stage clinical biopharmaceutical firm headquartered in Research Triangle Park, NC. The company leverages its proprietary PRINT® particle engineering technology to develop and commercialize innovative therapies. This platform is designed to enhance the safety, efficacy, and performance of a broad spectrum of treatments. Liquidia's current focus is on two key product candidates: LIQ861 for pulmonary arterial hypertension (PAH) and LIQ865 for local post-operative pain, for which it holds worldwide commercial rights. The company's commitment to transforming patient lives through advanced drug delivery systems is central to its mission.
How much funding has Liquidia raised?
Liquidia has raised a total of $233M across 7 funding rounds:
Series A
$6M
Series B
$16M
Series C
$25M
Series D
$25.5M
Debt
$20.5M
Debt
$40M
Debt
$100M
Series A (2006): $6M with participation from Siemens, Wakefield Group, Next47, and Firelake Capital
Series B (2007): $16M led by New Enterprise Associates, Wakefield Group, and Firelake Capital
Series C (2010): $25M supported by New Enterprise Associates, Canaan Partners, Firelake Capital, and Pappas Capital
Series D (2018): $25.5M featuring New Enterprise Associates, Canaan Partners, Morningside Group, and Xeraya Capital
Debt (2021): $20.5M backed by Silicon Valley Bank
Debt (2022): $40M with participation from Silicon Valley Bank
Debt (2025): $100M, investors not publicly disclosed
Key Investors in Liquidia
New Enterprise Associates
New Enterprise Associates (NEA) is a prominent venture capital firm established in 1977, known for its focus on helping entrepreneurs build businesses across various sectors.
Canaan Partners
Canaan is an early-stage venture capital firm that invests in technology and healthcare companies, backing founders from seed through growth stages in areas such as enterprise software, fintech, consumer, biopharma, and digital health.
Firelake Capital
Firelake Strategic Technology Fund invests in energy technology, communications technology, and materials companies, focusing on groundbreaking proprietary technology directed to large markets.
What's next for Liquidia?
With substantial enterprise-level capital secured, Liquidia is poised for significant growth and advancement in its clinical development programs. The recent strategic investment signals strong confidence from backers in the company's technology and therapeutic pipeline. This financing is expected to accelerate the progression of LIQ861 and LIQ865 through clinical trials and towards commercialization. Liquidia's strategic use of its proprietary PRINT® technology positions it to address unmet needs in critical therapeutic areas, potentially leading to substantial market impact and improved patient outcomes. The company's trajectory suggests a focus on scaling operations and expanding its portfolio through continued innovation and strategic partnerships.
See full Liquidia company page
